The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There were 16 responders (from here on, referred to as R) and 26 nonresponders (NR), yielding a response rate of 38%, which is in line with published clinical data of anti–PD-1 therapy in metastatic melanoma patients (5, 6).”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [6]
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [5]
In the citing paper
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [73]
In the citing paper
“In the subsequent phase III clinical trial, more than 30% of patients with advanced melanoma achieved an objective response following pembrolizumab monotherapy compared with 12% of patients treated with ipilimumab alone (58).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [58]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [2]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [4]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Research works printed but not linked: 2
- Ribas A, 2014, Pigment Cell Melanoma Res, 27, 1223
- Robert C, 2014, Ann Oncol, 25, LBA34
Cited by
Sorted by citations
Items 701–800 of 1,039
Redelman‐Sidi, G., Michielin, O. A., Cervera, C., Ribi, C., Aguado, J. M., Fernández‐Ruiz, M., & Manuel, O. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.030 · Cited by 127
Tio, M., Rai, R., Ezeoke, O. M., McQuade, J. L., Zimmer, L., Khoo, C. C. H., Park, J., Spain, L. A., Turajlic, S., Ardolino, L., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.017 · Cited by 127
Self-citationReardon, D. A., Kim, T. M., Frenel, J., Simonelli, M., Lopez, J. S., Subramaniam, D. S., Siu, L. L., Wang, H., Krishnan, S., Stein, K. F., et al. (2021) · Cancer · doi:10.1002/cncr.33378 · Cited by 127
O’Malley, D. M., Oaknin, A., Monk, B. J., Selle, F., Rojas, C., Gladieff, L., Berton, D., Leary, A. F., Moore, K. N., Estevez-Diz, M. D. P., et al. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.08.018 · Cited by 127
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
Nosrati, A., Tsai, K. K., Goldinger, S. M., Tumeh, P. C., Grimes, B. A., Loo, K. L., Algazi, A. P., Nguyen‐Kim, T. D. L., Levesque, M. P., Dummer, R., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.70 · Cited by 126
Self-citationImmune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126
Immune Checkpoint Inhibitor Toxicity
Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 126
Self-citationSeremet, T., Jansen, Y. J. L., Planken, S., Njimi, H., Delaunoy, M., Housni, H. E., Awada, G., Schwarze, J. K., Keyaerts, M., Everaert, H., et al. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-2051-8 · Cited by 126
Self-citationRole of Inducible Co-Stimulator (ICOS) in cancer immunotherapy
Amatore, F., Gorvel, L., & Olive, D. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1693540 · Cited by 126
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
Kostine, M., Cleven, A. H. G., de Miranda, N. F. C. C., Italiano, A., Cleton-Jansen, A., & Bovée, J. V. M. G. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.108 · Cited by 125
The expanding role of immunotherapy
Martín-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J. A., & Tabernero, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.008 · Cited by 125
Immunotherapy in advanced gastric cancer, is it the future?
Coutzac, C., Pernot, S., Chaput, N., & Zaanan, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.007 · Cited by 125
Peptide-based materials for cancer immunotherapy
Zhang, L., Huang, Y., Lindstrom, A. R., Lin, T., Lam, K. S., & Li, Y. (2019) · Theranostics · doi:10.7150/thno.37194 · Cited by 125
Clinical pharmacology considerations for the development of immune checkpoint inhibitors
Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Abdel-Rahman, O. M., & Fouad, M. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816636557 · Cited by 124
Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Şenbabaoğlu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.007 · Cited by 124
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Egelston, C. A., Avalos, C., Tu, T. Y., Simons, D. L., Jimenez, G., Jung, J. Y., Melstrom, L. G., Margolin, K. A., Yim, J. H., Kruper, L. L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06653-9 · Cited by 124
The Current Landscape of NKT Cell Immunotherapy and the Hills Ahead
Nelson, A., Lukacs, J., & Johnston, B. (2021) · Cancers · doi:10.3390/cancers13205174 · Cited by 124
Kim, R., Kwon, M., An, M., Kim, S. T., Smith, S. A., Loembé, A., Mortimer, P. G. S., Armenia, J., Lukashchuk, N., Shah, N., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.10.009 · Cited by 124
Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., Cristofanilli, M., Sosman, J. A., & Giles, F. J. (2017) · Oncotarget · doi:10.18632/oncotarget.13315 · Cited by 123
Can immunostimulatory agents enhance the abscopal effect of radiotherapy?
Lévy, A., Chargari, C., Marabelle, A., Perfettini, J., Magné, N., & Deutsch, É. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.067 · Cited by 122
Du, W., Seah, I. Y. J., Bougazzoul, O., Choi, G., Meeth, K. M., Bosenberg, M., Wakimoto, H., Fisher, D. E., & Shah, K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700363114 · Cited by 123
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Chen, R. Q., Liu, F., Qiu, X. Y., & Chen, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01503 · Cited by 123
Su, Z., Xiao, Z., Wang, Y., Huang, J., An, Y., Wang, X., & Shuai, X. (2020) · Small · doi:10.1002/smll.201906832 · Cited by 123
Yang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12534 · Cited by 124
Pierini, S., Gabbasov, R. T., Oliveira-Nunes, M. C., Qureshi, R., Worth, A. M., Huang, S., Nagar, K. K., Griffin, C., Lian, L., Yashiro–Ohtani, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-55770-1 · Cited by 123
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Abdelhamed, S., Ogura, K., Yokoyama, S., Saiki, I., & Hayakawa, Y. (2016) · Journal of Cancer · doi:10.7150/jca.14713 · Cited by 122
Review: Immune‐Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Suarez-Almazor, M. E., Kim, S. T., Abdel‐Wahab, N., & Diab, A. K. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40043 · Cited by 122
Elassaiss‐Schaap, J., Rossenu, S., Lindauer, A., Kang, S., de Greef, R., Sachs, J., & de Alwis, D. (2016) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12132 · Cited by 121
Peptide vaccines in cancer — old concept revisited
Kumai, T., Kobayashi, H., Harabuchi, Y., & Celis, E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.11.001 · Cited by 121
Prasad, V. K., & Kaestner, V. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.007 · Cited by 121
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity
Tucci, M., Mannavola, F., Passarelli, A. M., Stucci, L. S., Cives, M., & Silvestris, F. (2018) · Oncotarget · doi:10.18632/oncotarget.24846 · Cited by 121
Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors
Ji, C., Roy, M. D., Golas, J., Vitsky, A., Ram, S., Kumpf, S. W., Martin, M. T., Barletta, F., Meier, W. A., Hooper, A. T., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4083 · Cited by 122
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., & Gutzmer, R. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 120
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 120
Anderson, E. S., Postow, M. A., Wolchok, J. D., Young, R. J., Ballangrud, Å., Chan, T. A.-T., Yamada, Y. J., & Beal, K. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0282-x · Cited by 120
Buder‐Bakhaya, K., Benesova, K., Schulz, C., Anwar, H., Dimitrakopoulou‐Strauss, A., Weber, T. F., Enk, A., Lorenz, H., & Hassel, J. C. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2069-9 · Cited by 120
Queirolo, P., Boutros, A., Tanda, E. T., Spagnolo, F., & Quaglino, P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.001 · Cited by 120
The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
Jia, X., Geng, L., Jiang, P., Xu, H., Nan, K., Yao, Y., Jiang, L., Sun, H., Qin, T., & Guo, H. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01749-x · Cited by 120
Microneedles for gene and drug delivery in skin cancer therapy
Zhi, D., Yang, T., Zhang, T., Yang, M. J., Zhang, S., & Donnelly, R. F. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.009 · Cited by 120
The benefits of immunotherapy combinations
Schmidt, C. W. (2017) · Nature · doi:10.1038/d41586-017-08702-7 · Cited by 119
Brown, Z. J., Yu, S. J., Heinrich, B., Ma, C., Fu, Q., Sandhu, M., Agdashian, D., Zhang, Q., Korangy, F., & Greten, T. F. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2190-4 · Cited by 119
Master protocol trials in oncology: Review and new trial designs
Hirakawa, A., Asano, J., Sato, H., & Teramukai, S. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.009 · Cited by 120
Predictors of Immunotherapy-Induced Immune-Related Adverse Events
Kartolo, A., Sattar, J., Sahai, V., Baetz, T. D., & Lakoff, J. M. (2018) · Current Oncology · doi:10.3747/co.25.4047 · Cited by 119
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119
Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients
Wohlmuth, C., Wieser, I., May, T., Vicus, D., Gien, L. T., & Laframboise, S. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00487-x · Cited by 119
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma
Chang, C., Park, H., Malone, D. C., Wang, C.-Y., Wilson, D. L., Yeh, Y., van Boemmel-Wegmann, S., & Lo-Ciganic, W.-H. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1611 · Cited by 119
Basler, L., Gabryś, H. S., Hogan, S. A., Pavic, M., Bogowicz, M., Vuong, D., Tanadini‐Lang, S., Forster, R. E., Kudura, K., Huellner, M. W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0020 · Cited by 119
Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, R., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 119
Lopci, E., Hicks, R. J., Dimitrakopoulou‐Strauss, A., Dercle, L., Iravani, A., Seban, R., Sachpekidis, C., Humbert, O., Gheysens, O. S., Glaudemans, A. W. J. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05780-2 · Cited by 119
Robert, C., Carlino, M. S., McNeil, C. M., Ribas, A., Grob, J., Schachter, J., Nyakas, M., Kee, D., Petrella, T. M., Blaustein, A. S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01599 · Cited by 119
Self-citationCirculating tumour DNA (CtDNA) as a liquid biopsy for melanoma
Calapre, L., Warburton, L., Millward, M., Ziman, M., & Gray, E. S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.030 · Cited by 118
Williams, N. L., Wuthrick, E. J., Kim, H. J., Palmer, J. D., Garg, S., Eldredge-Hindy, H., Daskalakis, C., Feeney, K. J., Mastrangelo, M. J., Kim, L. J., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.05.028 · Cited by 118
Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.007 · Cited by 118
Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations
Gatti-Mays, M. E., Redman, J. M., Collins, J. M., & Bilušić, M. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1364322 · Cited by 118
Wang, T., Wu, X., Guo, C., Zhang, K., Xu, J., Li, Z., & Jiang, S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00990 · Cited by 119
George, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 118
Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity
Wang, G., Chow, R. D.-W., Bai, Z., Zhu, L., Errami, Y., Dai, X., Dong, M. B., Ye, L., Zhang, X., Renauer, P. A., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0500-4 · Cited by 120
Cancer biomarkers for targeted therapy
Liu, D. (2019) · Biomarker Research · doi:10.1186/s40364-019-0178-7 · Cited by 118
Zhu, B., Tang, L., Chen, S., Yin, C., Peng, S., Li, X., Liu, T., Liu, W., Han, C., Stawski, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0314-0 · Cited by 117
PD-L1 expression as a potential predictive biomarker
Fusi, A., Festino, L., Botti, G., Masucci, G. V., Melero, I., Lorigan, P. C., & Ascierto, P. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00307-1 · Cited by 117
Self-citationImmune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 117
Multiple sclerosis outcomes after cancer immunotherapy
García, C. R., Jayswal, R. D., Adams, V. R., Anthony, L. B., & Villano, J. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02060-8 · Cited by 117
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors
Kennedy, L. C., Bhatia, S., Thompson, J. A., & Grivas, P. D. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.7310 · Cited by 117
Yang, P., Lu, C. T., Qin, W., Chen, M., Quan, G., Liu, H., Wang, L., Bai, X., Pan, X., & Wu, C. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.12.037 · Cited by 117
The Treatment of Advanced Melanoma: Therapeutic Update
Villani, A., Potestio, L., Fabbrocini, G., Troncone, G., Malapelle, U., & Scalvenzi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126388 · Cited by 117
Tetzlaff, M. T., Nagarajan, P., Chon, S. Y., Huen, A., Diab, A. K., Pacha, O., Aung, P. P., Torres-Cabala, C. A., Mays, S. R., Prieto, V. G., et al. (2017) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000000688 · Cited by 116
Vosoughi, E., Lee, J. M., Miller, J. R., Nosrati, M., Minor, D. R., Abendroth, R. E., Lee, J. W., Andrews, B. T., Leng, L. Z., Wu, M. C., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4374-x · Cited by 116
Broos, K., Keyaerts, M., Lecocq, Q., Renmans, D., Nguyen, T. T., Escors, D., Liston, A., Raes, G., Breckpot, K., & Devoogdt, N. (2017) · Oncotarget · doi:10.18632/oncotarget.16708 · Cited by 115
Wong, S. Q., Raleigh, J., Callahan, J., Vergara, I. A., Ftouni, S., Hatzimihalis, A., Colebatch, A. J., Li, J., Semple, T. J., Doig, K., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00009 · Cited by 115
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 115
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 115
Rosato, R. R., Dávila‐González, D., Choi, D. S., Qian, W. P., Chen, W., Kozielski, A. J., Wong, H. H., Dave, B., & Chang, J. C. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1037-4 · Cited by 115
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma
Grossmann, K. F., Othus, M., Patel, S. P., Tarhini, A. A., Sondak, V. K., Knopp, M. V., Petrella, T. M., Truong, T.-G., Khushalani, N. I., Cohen, J. V., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1141 · Cited by 115
Self-citationLander, V. E., Belle, J. I., Kingston, N. L., Herndon, J. M., Hogg, G. D., Liu, X., Kang, L.-I., Knolhoff, B. L., Bogner, S. J., Baer, J. M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0192 · Cited by 114
Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
Kim, N., & Kim, H. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02041 · Cited by 117
Nakamura, Y., Tanaka, R., Maruyama, H., Ishitsuka, Y., Okiyama, N., Watanabe, R., Fujimoto, M., & Fujisawa, Y. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy201 · Cited by 114
Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy
Knudson, K. M., Hicks, K. C., Alter, S., Schlom, J., & Gameiro, S. R. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0551-y · Cited by 114
Ugurel, S., Röhmel, J., Ascierto, P. A., Becker, J. C., Flaherty, K. T., Grob, J., Hauschild, A., Larkin, J., Livingstone, E., Long, G. V., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.021 · Cited by 114
Self-citationZheng, S.-J., Yang, M., Luo, J., Liu, R., Song, J., Chen, Y., & Du, J. (2023) · ACS Nano · doi:10.1021/acsnano.3c03962 · Cited by 114
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 114
Murakami, N., Borges, T. J., Yamashita, M., & Riella, L. V. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw024 · Cited by 113
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights
Xue, G., Romano, E., Massi, D., & Mandalà, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.009 · Cited by 113
Kang, S., Gergich, K., Lubiniecki, G. M., de Alwis, D. P., Chen, C., Tice, M. A. B., & Rubin, E. H. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx076 · Cited by 113
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
Mittica, G., Ghisoni, E., Giannone, G., Aglietta, M., Genta, S., & Valabrega, G. (2017) · Oncotarget · doi:10.18632/oncotarget.20042 · Cited by 113
Berger, K., & Pu, J. J. (2017) · Gene · doi:10.1016/j.gene.2017.09.050 · Cited by 113
Thyroid disorders induced by checkpoint inhibitors
Ferrari, S. M., Fallahi, P., Galetta, F., Citi, E., Benvenga, S., & Antonelli, A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9463-2 · Cited by 113
Dong, M., Meng, Z., Kuerban, K., Qi, F., Liu, J., Wei, Y., Wang, Q., Jiang, S., Feng, M., & Ye, L. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1099-3 · Cited by 113
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆
Owen, C. N., Shoushtari, A. N., Chauhan, D., Palmieri, D. J., Lee, B., Rohaan, M. W., Mangana, J., Atkinson, V. G., Zaman, F. Y., Young, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.471 · Cited by 113
Self-citationTumor microenvironment in head and neck squamous cell carcinoma: Functions and regulatory mechanisms
Wang, G., Zhang, M., Cheng, M., Wang, X., Li, K., Chen, J., Chen, Z., Chen, S., Chen, J., Xiong, G., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.009 · Cited by 113
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 112
Toxicity management of immunotherapy for patients with metastatic melanoma
Linardou, H., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.10 · Cited by 112
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 113
Myositis as an adverse event of immune checkpoint blockade for cancer therapy
Shah, M., Tayar, J. H., Abdel‐Wahab, N., & Suarez-Almazor, M. E. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.05.006 · Cited by 112
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Reynolds, K. L., Thomas, M. F., & Dougan, M. L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0174 · Cited by 112
Metadata
- Authors
- Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., & Ribas, A.
- Affiliations
- Université Paris-Sud (FR)
- Sheba Medical Center (IL)
- Hospital Clínic de Barcelona (ES)
- Hôpital de la Timone (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- University of California, San Francisco (US)
- Royal Prince Alfred Hospital (AU)
- Hadassah Medical Center (IL)
- Royal Marsden Hospital (GB)
- University of Manchester (GB)
- Universitair Ziekenhuis Brussel (BE)
- The Netherlands Cancer Institute (NL)
- Angeles Clinic and Research Institute (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2521-2532
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152897456
- Semantic Scholar
- 0dac3ea80083f0a86598cb9af0a205554280551b
- Cited by
- 5,887
- References
- 26
- Citations by year
- 2026: 234 · 2025: 298 · 2024: 374 · 2023: 421 · 2022: 471 · 2021: 568 · 2020: 659 · 2019: 585 · 2018: 684 · 2017: 761 · 2016: 628 · 2015: 188
- FWCI
- 329.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Genentech
- Kite Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 inhibition, progression-free survival, overall survival, dosing frequency, treatment-related adverse events, immune-related adverse events, response rate
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
